SEC Form 13F Information Table Summary
Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Takeda Pharmaceutical Co Ltd for the reporting period ending March 31, 2024. The document discloses the company's holdings in equity securities, detailing the number of shares, value, and voting authority for various issuers.
Key Financial Metrics and Holdings
The filing does not report Takeda's own revenue, profit, cash flow, or debt metrics. Instead, it lists specific equity positions held by the company. Notable holdings include:
- Denali Therapeutics Inc.: 4,214,559 shares with sole voting authority.
- HilleVax, Inc.: 6,724,000 shares with shared voting authority.
- Phathom Pharmaceuticals, Inc.: 3,153,217 shares with sole voting authority.
- Ovid Therapeutics Inc.: Total of 7,531,996 shares (split between shared and sole voting authority).
- Equillium, Inc.: 1,824,977 shares with shared voting authority.
The filing lists 17 distinct positions across biotechnology and healthcare-related companies. The "Value" column in the source text is present but contains no numerical data for the total portfolio value or individual position values.
Material Changes and Outlook
The filing text does not provide comparative data against the prior period, nor does it contain management commentary, guidance, risk factors, or contingencies. It is a static snapshot of holdings as of the reporting date.
Investor Verification Checklist
- Verify the total aggregate value of the disclosed portfolio, as the source text lists share counts but omits dollar values.
- Confirm the voting authority status (Sole, Shared, or None) for each position to understand Takeda's influence on these investees.
- Check subsequent filings to determine if these positions were liquidated or increased in the following quarter.
- Review the specific CUSIP numbers to ensure accurate identification of the securities, particularly for companies with multiple share classes.